The trivalent arsenical preparation meta-aminoparahydroxyphenylarsine oxide was studied originally by Ehrlich and Bertheim and later by Voegtlin and others. Ehrlich and Hata1 found its therapeutic index to be less than that of the arsphenamines. Voegtlin2 considered arsenoxide for clinical use in the treatment of syphilis but hesitated because its margin of safety as established by the chemotherapeutic index appeared to be somewhat lower than that of arsphenamine. The attention of chemotherapeutists was again called to arsenoxide as the result of the experiments of Tatum and Cooper.3 These investigators found that the therapeutic index and other properties were such as to make the drug more promising than any other single antisyphilitic agent. Gruhzit,4 in studies on experimental trypanosomiasis and syphilis, found that arsenoxide was well tolerated and possessed a therapeutic value at least as high as that of neoarsphenamine.
Mapharsen is meta-aminoparahydroxyphenylarsine oxide hydrochloride, generally known by
COLE HN, PALMER RB. MAPHARSEN IN THE TREATMENT OF SYPHILIS. Arch Derm Syphilol. 1937;36(3):561–580. doi:10.1001/archderm.1937.01480030088010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.